PARP1 and cancer: Such questions surrounding ALC1 regulation are increasingly important as recent studies show that abrogating ALC1 activity vastly increases the efficacy of PARP inhibitors (Blessing et al., 2020; Verma et al., 2021) and may even be useful for treatment of PARP inhibitor-resistant cancers (Juhász et al., 2020).